News | May 01, 2024
Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion
2024 full-year revenue guidance raised by US$ 2 billion
2024 full-year revenue guidance raised by US$ 2 billion
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Innovent will supply sintilimab for the collaborated clinical trial
Express Scripts to add Zepbound to National Preferred Formulary
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Subscribe To Our Newsletter & Stay Updated
